prl data (Sanofi)
86
Structured Review
Sanofi
prl data
Prl Data, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prl+data/data+prl/pm41688144-74-6-14
Average 86 stars, based on 1 article reviews
Prl Data, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prl+data/data+prl/pm41688144-74-6-14
Average 86 stars, based on 1 article reviews
prl data - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
other:Article Title: Tolebrutinib and the FDA. Article Snippet: Recently, the US Food and Drug Administration (FDA) informed the Genzyme Corporation (a subsidiary of Sanofi) that its new drug application (NDA) for tolebrutinib, a second-generation Bruton tyrosine kinase inhibitor (BTKi), cannot be approved in its current form (FDA, 2025).. The primary obstacle to authorisation is a significant risk of severe liver injury, which the FDA believes outweighs the potential clinical benefits of tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS).. Despite attempts to manage this toxicity through intensive monitoring, the FDA identified several “life-threatening cases” during clinical trials. |